Lucid Capital downgraded INmune Bio (INMB) to Neutral from Buy with a $2 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Inmune Bio’s Phase 2 Trial Shows Promise in Alzheimer’s
- INmune Bio downgraded to Market Perform from Outperform at Raymond James
- INmune Bio downgraded at Raymond James after Alzheimer’s data ‘missed the mark’
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- INmune Bio reports findings from Phase 2 MINDFuL trial of XPro